Difference between revisions of "Ibritumomab tiuxetan (Zevalin)"
Line 1: | Line 1: | ||
==General information== | ==General information== | ||
− | Class/mechanism: | + | Class/mechanism: Anti-CD20 antibody chelated by tiuxetan to a radioactive agent (Y-90, yttrium-90; or In-111, indium-111). Y-90 emits beta radiation, which causes cellular damage via free radicals. This results in damage to cells which express the CD20 antigen (human B-lymphocyte-restricted differentiation antigen, Bp35).<ref name="insert">[http://www.zevalin.com/v3/pdf/Zevalin_PI_Website.pdf Ibritumomab tiuxetan (Zevalin) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/ibritumomab.pdf Ibritumomab tiuxetan (Zevalin) package insert (locally hosted backup)]</ref> |
− | + | <br>Route: IV | |
− | + | <br>Extravasation: potential [[vesicant]] | |
− | |||
− | |||
− | <ref name="insert">[http://www.zevalin.com/v3/pdf/Zevalin_PI_Website.pdf Ibritumomab (Zevalin) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/ibritumomab.pdf Ibritumomab (Zevalin) package insert (locally hosted backup)]</ref> | ||
− | <br>Route: | ||
− | <br>Extravasation: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | ||
==Patient drug information== | ==Patient drug information== | ||
− | *[http://chemocare.com/bio/ibritumomab.asp Ibritumomab (Zevalin) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/ibritumomab.asp Ibritumomab (Zevalin) patient drug information (Chemocare)]</ref> | + | *[http://chemocare.com/bio/ibritumomab.asp Ibritumomab tiuxetan (Zevalin) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/ibritumomab.asp Ibritumomab tiuxetan (Zevalin) patient drug information (Chemocare)]</ref> |
− | *[http://www.uptodate.com/contents/ibritumomab-patient-drug-information Ibritumomab (Zevalin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ibritumomab-patient-drug-information Ibritumomab (Zevalin) patient drug information (UpToDate)]</ref> | + | *[http://www.uptodate.com/contents/ibritumomab-patient-drug-information Ibritumomab tiuxetan (Zevalin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ibritumomab-patient-drug-information Ibritumomab tiuxetan (Zevalin) patient drug information (UpToDate)]</ref> |
==References== | ==References== | ||
<references/> | <references/> |
Revision as of 21:50, 10 February 2012
General information
Class/mechanism: Anti-CD20 antibody chelated by tiuxetan to a radioactive agent (Y-90, yttrium-90; or In-111, indium-111). Y-90 emits beta radiation, which causes cellular damage via free radicals. This results in damage to cells which express the CD20 antigen (human B-lymphocyte-restricted differentiation antigen, Bp35).[1][2]
Route: IV
Extravasation: potential vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
- Ibritumomab tiuxetan (Zevalin) patient drug information (Chemocare)[3]
- Ibritumomab tiuxetan (Zevalin) patient drug information (UpToDate)[4]